RecruitingNCT03547856

A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients"


Sponsor

Yan Li

Enrollment

10,000 participants

Start Date

Jul 18, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

24 hour ambulatory blood pressure (ABP) monitoring should be the first choice for diagnosis and treatment of hypertension according to European Societyof Hypertension (ESH) and the European Society of Cardiology (ESC) guideline on ambulatory blood pressure monitoring. Finally, we should promote the clinical application of 24 hour ambulatory blood pressure monitoring to greatly improve the management level of hypertension in China and effectively reduce the risk caused by hypertension in the population. Information of hypertensive patients with ambulatory blood pressure monitoring was prospectively registered nationwide,and then to investigate whether there was difference in cardiovascular prognosis according to the control of ABP.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria5

  • Age 18-80 years old
  • Clinical diagnosed hypertension with the use of antihypertensive drugs
  • A 24-hour ambulatory blood pressure monitoring was performed with validated equipment.
  • Willing to provide information about disease history and blood biochemical test data within 6 months.
  • Sign the informed consent

Exclusion Criteria3

  • Without antihypertensive drug use
  • Hospitalized hypertension patients
  • Non-compliant patient

Locations(1)

Ruijin Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03547856


Related Trials